 Michael Knitz
Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 13 | 2024 | 527 | 2.640 |
Why?
| | T-Lymphocytes, Regulatory | 4 | 2022 | 377 | 0.810 |
Why?
| | Immunotherapy | 5 | 2025 | 579 | 0.780 |
Why?
| | Tumor Microenvironment | 9 | 2025 | 588 | 0.700 |
Why?
| | Radiation Tolerance | 1 | 2021 | 97 | 0.690 |
Why?
| | Carcinoma, Pancreatic Ductal | 5 | 2025 | 264 | 0.680 |
Why?
| | Ephrin-B2 | 4 | 2024 | 50 | 0.640 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 170 | 0.630 |
Why?
| | Receptor, EphB4 | 3 | 2024 | 36 | 0.600 |
Why?
| | Papillomavirus Infections | 1 | 2021 | 290 | 0.580 |
Why?
| | Dendritic Cells | 1 | 2021 | 478 | 0.570 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 732 | 0.520 |
Why?
| | Pancreatic Neoplasms | 5 | 2025 | 878 | 0.490 |
Why?
| | Cell Line, Tumor | 6 | 2025 | 3100 | 0.350 |
Why?
| | Mice | 15 | 2025 | 16543 | 0.320 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 3 | 2023 | 76 | 0.290 |
Why?
| | Adenocarcinoma | 2 | 2023 | 895 | 0.240 |
Why?
| | Interleukin-2 | 2 | 2023 | 427 | 0.240 |
Why?
| | PPAR alpha | 1 | 2024 | 58 | 0.230 |
Why?
| | Oleic Acid | 1 | 2024 | 38 | 0.220 |
Why?
| | Animals | 15 | 2025 | 34628 | 0.220 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2024 | 38 | 0.220 |
Why?
| | Interleukin-7 | 1 | 2024 | 58 | 0.220 |
Why?
| | Spiral Cone-Beam Computed Tomography | 1 | 2023 | 5 | 0.220 |
Why?
| | STAT3 Transcription Factor | 2 | 2022 | 187 | 0.210 |
Why?
| | Epithelial-Mesenchymal Transition | 2 | 2024 | 190 | 0.210 |
Why?
| | Tumor Burden | 2 | 2021 | 284 | 0.210 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 42 | 0.200 |
Why?
| | Vasculitis | 1 | 2023 | 68 | 0.200 |
Why?
| | Radioimmunotherapy | 1 | 2021 | 14 | 0.190 |
Why?
| | Combined Modality Therapy | 2 | 2022 | 1213 | 0.190 |
Why?
| | STAT1 Transcription Factor | 1 | 2021 | 69 | 0.190 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1230 | 0.180 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 25 | 0.180 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 41 | 0.180 |
Why?
| | ADAM10 Protein | 1 | 2021 | 30 | 0.180 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2021 | 30 | 0.180 |
Why?
| | Gamma Rays | 1 | 2021 | 52 | 0.180 |
Why?
| | Lymphocyte Depletion | 1 | 2021 | 129 | 0.180 |
Why?
| | Complement Inactivating Agents | 1 | 2021 | 44 | 0.180 |
Why?
| | Receptors, Complement | 1 | 2021 | 120 | 0.170 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 78 | 0.170 |
Why?
| | Mice, Knockout | 3 | 2021 | 2770 | 0.170 |
Why?
| | Radiation Injuries | 1 | 2021 | 139 | 0.160 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 203 | 0.160 |
Why?
| | Cell Proliferation | 3 | 2021 | 2337 | 0.150 |
Why?
| | Fibrosis | 1 | 2021 | 518 | 0.150 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2024 | 824 | 0.150 |
Why?
| | Membrane Proteins | 2 | 2021 | 1100 | 0.150 |
Why?
| | Repressor Proteins | 1 | 2021 | 400 | 0.140 |
Why?
| | Glioblastoma | 1 | 2020 | 311 | 0.140 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 5270 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1312 | 0.110 |
Why?
| | Biomarkers, Tumor | 1 | 2020 | 1170 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1905 | 0.110 |
Why?
| | Phenotype | 1 | 2021 | 3059 | 0.100 |
Why?
| | Humans | 15 | 2025 | 128896 | 0.090 |
Why?
| | Tumor Cells, Cultured | 2 | 2021 | 928 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 797 | 0.070 |
Why?
| | Cell Movement | 2 | 2021 | 932 | 0.060 |
Why?
| | Survival Rate | 2 | 2021 | 1884 | 0.060 |
Why?
| | Fenofibrate | 1 | 2024 | 30 | 0.060 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2023 | 31 | 0.050 |
Why?
| | CA-19-9 Antigen | 1 | 2023 | 23 | 0.050 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2023 | 166 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2024 | 608 | 0.050 |
Why?
| | Prognosis | 2 | 2021 | 3787 | 0.050 |
Why?
| | Lymph Node Excision | 1 | 2022 | 166 | 0.050 |
Why?
| | Apoptosis | 2 | 2021 | 2481 | 0.050 |
Why?
| | Fatty Acids | 1 | 2024 | 415 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 225 | 0.050 |
Why?
| | Neoadjuvant Therapy | 1 | 2023 | 383 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2021 | 182 | 0.040 |
Why?
| | Complement C3 | 1 | 2021 | 200 | 0.040 |
Why?
| | Signal Transduction | 2 | 2024 | 4857 | 0.040 |
Why?
| | Dexamethasone | 1 | 2021 | 330 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 479 | 0.040 |
Why?
| | Software | 1 | 2023 | 611 | 0.040 |
Why?
| | Mice, Nude | 1 | 2020 | 680 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 422 | 0.040 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2024 | 1040 | 0.040 |
Why?
| | Phosphorylation | 1 | 2020 | 1685 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3042 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 802 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2603 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1570 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2024 | 3994 | 0.030 |
Why?
| | Inflammation | 1 | 2023 | 2694 | 0.020 |
Why?
| | Female | 3 | 2025 | 68162 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 6568 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2023 | 10239 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2023 | 14546 | 0.020 |
Why?
|
|
Knitz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|